International journal of clinical oncology · 2026
Pain response to palliative intent conventional radiotherapy for painful malignant iliopsoas involvement: a multicenter retrospective study.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Makita Kenji, Ishikawa Yojiro, Wada Yuki, Fujisawa Takeshi, Hiroshima Yuichi, Wakabayashi Masashi, Saito Tetsuo
Аннотация
BACKGROUND: Evidence regarding the efficacy of palliative-intent conventional radiotherapy (conv-pRT) for painful malignant iliopsoas involvement (PMII), including malignant psoas syndrome (MPS)-related pain, caused by non-bone metastatic lesions remains limited to small, single-center studies. Therefore, we conducted the first multicenter study to evaluate the clinical effectiveness of conv-pRT for PMII/MPS.
METHODS: We retrospectively analyzed patients with PMII/MPS treated with conv-pRT between January 2013 and May 2025. Eligible patients received 8 Gy in 1 fraction, 20 Gy in 5 fractions, or 30 Gy in 10 fractions and had pain assessment available at ≥ 4 weeks after treatment initiation. Pain response was evaluated based on changes in pain scores and opioid consumption. Assessments were performed at 7 ± 3, 14 ± 3, 28 ± 7, and 56 ± 14 days from the start of conv-pRT. The best overall response (OR) during follow-up was determined.
RESULTS: A total of 54 patients were included. The median follow-up duration was 115 days (interquartile range, 62-186 days), and the 56-day survival rate was 86.8%. The best OR rate was 61%, including complete response in 24% and partial response in 37%, while 39% were classified as non-responders. Among responders, 91% achieved OR within 4 weeks. The best OR rate was not significantly associated with tumor burden parameters, including axial maximum diameter and clinical target volume, baseline Numerical Rating Scale score, baseline oral morphine equivalent dose, or the conv-pRT schedule.
CONCLUSION: Conv-pRT provided clinically meaningful pain relief in approximately half of patients with PMII/MPS and may represent an effective palliative treatment option.
METHODS: We retrospectively analyzed patients with PMII/MPS treated with conv-pRT between January 2013 and May 2025. Eligible patients received 8 Gy in 1 fraction, 20 Gy in 5 fractions, or 30 Gy in 10 fractions and had pain assessment available at ≥ 4 weeks after treatment initiation. Pain response was evaluated based on changes in pain scores and opioid consumption. Assessments were performed at 7 ± 3, 14 ± 3, 28 ± 7, and 56 ± 14 days from the start of conv-pRT. The best overall response (OR) during follow-up was determined.
RESULTS: A total of 54 patients were included. The median follow-up duration was 115 days (interquartile range, 62-186 days), and the 56-day survival rate was 86.8%. The best OR rate was 61%, including complete response in 24% and partial response in 37%, while 39% were classified as non-responders. Among responders, 91% achieved OR within 4 weeks. The best OR rate was not significantly associated with tumor burden parameters, including axial maximum diameter and clinical target volume, baseline Numerical Rating Scale score, baseline oral morphine equivalent dose, or the conv-pRT schedule.
CONCLUSION: Conv-pRT provided clinically meaningful pain relief in approximately half of patients with PMII/MPS and may represent an effective palliative treatment option.